We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Alio, a firm focused on wireless remote patient monitoring, has received FDA clearance to add potassium, hematocrit and hemoglobin monitoring to its non-invasive SmartPatch system.
Animal studies meant to support a medical device premarket approval application should be conducted using the device in its finished form, according to a final guidance the FDA issued yesterday.
Sponsors submitting a 510(k) application for certain soft contact lenses may demonstrate substantial equivalence to previous lenses instead of having to conduct a direct comparison to a prior device, the FDA said in a final guidance released yesterday.
In a pair of final guidances released Friday, the FDA laid out what it intends to do with multiple pandemic-era device policies and Emergency Use Authorizations (EUAs) when the public health emergency formally ends on May 11. Read More
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has proposed major reforms to its clinical trial regulations — including a 30-day maximum for reviewing new trial applications and a 10-day maximum for granting a decision after receiving requested follow-up information. Read More
The FDA is standing up a new program to provide a framework for regulators, researchers and the public to explore how digital health technologies (DHT) — such as mobile medical apps and wearable devices — can advance drug development. Read More
The European Medicines Agency (EMA) reported “remarkable” progress, despite the pandemic, in a mid-point assessment of its “Regulatory Science Strategy to 2025” to build a more adaptive regulatory system that will encourage innovation — including advances in clinical trial innovation and a new real-world data (RWD) network. Read More
The FDA said it could not approve AbbVie’s new drug application (NDA) for ABBV-951 (foslevodopa/foscarbidopa), an investigational therapy for advanced Parkinson’s disease, because of concerns about the delivery device. Read More